The pharmacokinetics of 2,3-dideoxyadenosine (ddA), didanosine, 2,3-dideoxyguanosine (ddG), and 6-halogenated prodrugs of ddG, 6-chloro-ddG and 6-iodo-ddG, in plasma and cerebrospinal fluid (CSF) were studied in a non-human primate model. ddA was rapidly and completely deaminated to didanosine, such that didanosine concentration profiles in plasma and CSF were identical following administration of ddA and didanosine. The mean clearance of didanosine was 0.50 liters/h/kg, the terminal half-life was 1.8 h, and the CSF-to-plasma ratio was 4.8%. The disposition of ddG was similar, with a clearance of 0.70 liters/h/kg and a half-life of 1.7 h. The adenosine deaminase-mediated conversion of the 6-halogenated-ddG prodrugs to ddG was rapid but incomplete (48% for 6-chloro-ddG and 29% for 6-iodo-ddG). The CSF-to-plasma ratios of ddG with equimolar doses of ddG, 6-chloro-ddG, and 6-iodo-ddG were 8.5, 24, and 17%, respectively, but the actual ddG exposures in CSF (area under the CSF concentration-time curve) were comparable for ddG (12.1 M ⅐ h) and the 6-halogenated-ddG prodrugs (18.8 M ⅐ h for 6-chloro-ddG, 9.3 M ⅐ h for 6-iodo-ddG). 6-Chloro-ddG was not detectable in plasma or CSF, and the CSF-to-plasma ratio of 6-iodo-ddG was 9.4%, so the higher CSF-to-plasma ratios of ddG with the administration of the 6-halogenated-ddG prodrugs does not appear to be the result of enhanced penetration of the prodrug and subsequent dehalogenation to ddG. The penetration of ddG into CSF exceeds that of didanosine and is enhanced by administration of the 6-halogenated prodrugs, although the mechanism of this enhanced penetration is unclear.
The devastating effects of human immunodeficiency virus encephalopathy underscore the importance of finding new antiretroviral agents which penetrate into the central nervous system (CNS) to treat this important component of the disease (7) . The currently approved antiretroviral drugs in clinical use are dideoxynucleoside analogs, including zidovudine, zalcitabine, and didanosine (ddI) (3) . We previously studied the penetration of a series of dideoxypyrimidine nucleoside analogs into cerebrospinal fluid (CSF) and demonstrated that it ranged from over 20% for zidovudine to less than 5% for zalcitabine and that the degree of penetration into CSF was determined by the nucleobase rather than the alterations to the ribose sugar (5) . In addition, in subsequent clinical trials the degree of drug penetration into CSF appeared to correlate with efficacy in treating AIDS dementia (19, 20) .
A number of dideoxypurine (ddP) nucleoside analogs have also demonstrated antiretroviral activity in in vitro screening assays (14, 15, 17, 21) , and ddI was recently approved for clinical use. 2Ј,3Ј-Dideoxyadenosine (ddA) has a degree of activity similar to that of ddI, but it is almost instantaneously deaminated to ddI in vivo (9) . A series of 6-halogenated 2Ј,3Ј-dideoxyguanosine (ddG) and ddI analogs which act as prodrugs of ddG and ddI are currently in the preclinical phase of drug development. The 6-halo-ddP analogs are more lipophilic than the parent drugs, as measured by n-octanol partitioning (22) , and were synthesized in an attempt to improve the penetration of ddG and ddI into the CNS (17, 21, 22) . Studies in rodents have demonstrated enhanced penetration of the 6-halo-ddP prodrugs into the CNS as well as enhanced penetration of ddG and ddI, presumably as a result of dehalogenation of the 6-halo-ddPs by adenosine deaminase in the CNS (ADA) (16, 22) .
In the current study a previously described non-human primate model was used to study the pharmacokinetics of a series of ddP nucleoside analogs in plasma and CSF in an attempt to identify factors which promote better penetration into the CNS.
MATERIALS AND METHODS
Chemicals and drugs. Heptafluorobutyric acid was purchased from Pierce Chemical Company (Rockford, Ill.). Acetonitrile and methanol were high-pressure liquid chromatography (HPLC) grade and were from Fisher Scientific Company (Pittsburgh, Pa.). 2Ј-Deoxyadenosine (dA) and ammonium phosphate were obtained from Sigma Chemical Company (St. Louis, Mo.). ddA, ddG, ddI, and the ADA inhibitor 2Ј-deoxycoformycin (DCF) were provided by the Pharmaceutical Resources Branch, National Cancer Institute (Bethesda, Md.). 6-ClddG (Cl-ddG) and 6-I-ddG (I-ddG) were synthesized by previously published methods (17) .
Monkeys. Adult male rhesus monkeys (Macaca mulatta) weighing 6 to 12 kg were used in the experiments. The animals were fed National Institutes of Health Open Formula Extruded Non-Human Primate Diet twice daily and were housed in groups in accordance with the Guide for the Care and Use of Laboratory Animals (18) . Blood samples were drawn from a catheter placed in either the femoral or saphenous vein contralateral to the site of drug administration. CSF was collected from a chronically indwelling subcutaneous Ommaya reservoir attached to a fourth ventricular Pudenz catheter (13) .
Experiments. Blood samples following ddA, Cl-ddG, and I-ddG administration were collected into tubes containing DCF (final concentration, 10 M). When incubated in whole blood at room temperature, 75% of the Cl-ddG and 10% of the I-ddG were converted to ddG within 15 min. The addition of DCF to whole blood prior to the addition of Cl-ddG significantly inhibited the ADAmediated dehalogenation of Cl-ddG. Without DCF, the decay half-life of Cl-ddG is Ͻ10 min, and in the presence of 2 M DCF it is Ͼ24 h. In plasma and CSF at room temperature, less than 1% of the Cl-ddG was dehalogenated to ddG at 15 min. All blood samples drawn from the animals were immediately placed on ice and centrifuged at 4ЊC, and the plasma was then immediately frozen. CSF samples were also frozen immediately.
ddA was administered intravenously to three animals. Animal 631T received 100 mg/kg of body weight (0.43 mmol/kg of body weight) over 17 min, animal U340 received 96 mg/kg (0.41 mmol/kg) over 55 min, and animal 73Q received 74 mg/kg (0.31 mmol/kg) over 30 min. Blood and CSF samples were drawn into syringes containing DCF. ddI was administered intravenously to animal 73Q at a dose of 74 mg/kg (0.31 mmol/kg) over 30 min and to animal U340 at a dose of 77 mg/kg (0.33 mmol/kg) over 41 min. ddG and the 6-halo-ddG analogs were administered in equimolar doses. The 6-halo-ddG analogs were dissolved in dimethyl sulfoxide (DMSO) and were diluted with a phosphate-buffered salt solution to a final DMSO fraction of 33%. Four animals (animals 594PR, X940, CH843, and CH955) received ddG intravenously at a dose of 23.2 mg/kg (0.092 mmol/kg) over 10 min. The first three animals (animals 631T, U340, and 141) received Cl-ddG at 25 mg/kg (0.093 mmol/kg) intravenously over 10 min, and the samples were collected in heparinized tubes without DCF. Another two animals (animals 594PR and 141) received the same dose of Cl-ddG, and blood samples were collected into tubes containing DCF. I-ddG was administered intravenously to three animals (animals 705, 594PR, and 141) at a dose of 33.5 mg/kg (0.093 mmol/kg) over 10 min, and blood samples were collected into tubes containing DCF. Blood and CSF samples were obtained during and after the infusions at frequent intervals to 24 h (see Fig. 2 and 3 for the times that the samples were obtained).
Sample analysis. The ddP nucleoside concentrations in plasma and CSF were measured by paired-ion or reverse-phase HPLC methods (4) . dA was added to samples containing ddA or ddI as an internal standard. Plasma samples initially underwent a solid-phase extraction with C 18 Sep-PAK cartridges (Waters Associates, Milford, Mass.). After priming the cartridges with 6 ml of methanol and then 12 ml of water, 1-ml plasma samples were slowly loaded, washed with 2 ml of water, and eluted slowly with 2 ml of 100% methanol. The methanol was evaporated to dryness under a stream of nitrogen, and the samples were reconstituted in 200 l of water. Prior to injection onto the HPLC column, the samples were clarified by centrifugation through Ultrafree-MC 0.45-m-pore-size filter units (Millipore, Bedford, Mass.). Recovery of the ddPs after solid-phase extraction, which was calculated by comparison with an aqueous standard containing the same concentration as the plasma standard, exceeded 90%. CSF was either directly injected or extracted in the same manner as plasma, except that only 1 ml of water was used to wash samples prior to methanol elution.
Chromatography was performed on a Waters HPLC system consisting of a WISP model 710B injector, two model 510 solvent delivery pumps, an automated gradient controller, and a model 490 programmable wavelength UV detector. The mobile phase for both ddA and ddI analyses consisted of 10 mM ammonium phosphate (native pH) with 10% methanol at a flow rate of 1.5 ml/min through a C 18 Nova-PAK radial compression cartridge (8 mm by 10 cm) contained in a Z-module (Waters). UV monitoring was at 248 nm for ddI and 260 nm for ddA. The retention times for ddI, dA (internal standard), and ddA under these conditions were 4.6, 5.3, and 12.0 min, respectively. The lower limit of detection for ddI was 0.1 M, and the assay was linear up to 100 M; the within-and between-day coefficients of variation was less than 10%.
For ddG and the 6-halo-ddG analogs, a previously reported paired-ion technique was modified (4). The mobile phase consisted of heptafluorobutyric acid (0.1% [vol/vol]) with 8% acetonitrile for ddG and Cl-ddG and 10% acetonitrile for I-ddG at a flow rate of 2.0 ml/min through a Waters 4-m, C 18 Nova-PAK radial compression cartridge (8 mm by 10 cm) in a Z-module. The eluent was monitored at wavelengths of 252 and 260 nm. Under these conditions ddG eluted at 4 min, Cl-ddG eluted at 6.1 min, and I-ddG, which was monitored at 316 nm, eluted at 6.2 min. These samples were processed with external standards. The lower limit of detection for ddG and the 6-halo-ddG analogs was 0.1 M, and the assay was linear to 100 M. The within-and between-day coefficients of variation for ddG were less than 10%.
Pharmacokinetic and statistical analyses. The pharmacokinetic models shown in Fig. 1 were fit to plasma and CSF ddP concentration-versus-time data (weighted to 1/concentration 2 ) by using MLAB, a nonlinear curve-fitting program (12) . Because of the small volume of the CSF compartment and the relatively low concentration of drug in CSF, we assumed that the transfer of drug to and from the CSF compartment had no significant impact on the concentration in other compartments, and therefore, data for CSF were fitted after the parameters were estimated for the other compartments. The volume of the CSF compartment was assumed to be 0.015 liters in the models. ddA and Cl-ddG were metabolized so rapidly that too few datum points were available for modeling, and it was assumed in the model that conversion was instantaneous. The area under the concentration-time curve (AUC) was calculated by the trapezoidal method and was extrapolated to infinity (8) . The fraction of drug penetrating into the CSF was derived from the ratio of the AUCs in CSF and plasma.
The statistical significance of differences in drug penetration into CSF as measured by the ratio of the AUC in CSF to that in plasma were assessed by the unpaired, nonparametric Mann-Whitney U test. RESULTS ddA and ddI. ddA was eliminated extremely rapidly, presumably by deamination to ddI. In animal 631T, which received the highest dose and shortest infusion of ddA, the clearance of ddA, calculated from the steady-state concentration in plasma of 58 M, was 30 liters/h/kg. Drug was detectable for less than 20 min after the end of the infusion, and the half-life was estimated to be 24 s. Parent drug was not detectable in animal U340, which received a 1-h infusion. In animal 73Q, ddA was detectable only during the infusion of drug and the clearance was 24 liters/h/kg. The ddA concentration in the CSF of animal 631T peaked (30 min) at 0.4 M and was not detectable in the other two animals.
The pharmacokinetic parameters for ddI in the three animals receiving ddA and the two animals receiving ddI are listed in Table 1 . The mean AUC for ddI normalized to a dose of 0.43 mmol/kg was 906 M ⅐ h for the three animals receiving ddA and 667 M ⅐ h for the two animals receiving ddI, supporting the assumption that all of the ddA was converted to ddI. As shown in Fig. 2 , which depicts the profiles of ddI in the plasma and CSF of one animal receiving both ddA and ddI, the disappearance of ddI from plasma was biexponential. Although not as rapid as the elimination of ddA, the elimination of ddI was rapid, with a total clearance of 0.50 liters/h/kg and a terminal half-life of 1.8 h. Figure 2 also illustrates that administration of ddA results in a plasma concentration profile of ddI that is comparable to that achieved with an equimolar dose of ddI. For comparative analyses, the pharmacokinetic parameters for ddI from the three doses of ddA and the two doses of ddI were combined.
The penetration of ddI into CSF, derived from the ratio of the AUC of ddI in CSF to that in plasma, was limited (mean, 4.8%). This value represents the ratio of total drug exposure in CSF to that in plasma. We also calculated the CSF-to-plasma ratio for each individual time point by dividing the ddI concentration in CSF by the simultaneous concentration in plasma. This technique is frequently used in humans, because only one CSF sample can be obtained after administration of a dose of the drug. The CSF-to-plasma ratios calculated from individual concentrations ranged from 0.20 to 17.5%, and all of the individual CSF-to-plasma ratios at 2 h or later (mean, 10.0%) exceeded the CSF-to-plasma ratio calculated from the AUCs (mean, 4.8%). ddG and 6-halo-ddG analogs. The concentration profiles of ddG in plasma and CSF following administration of ddG, ClddG, and I-ddG are given in Fig. 3 , and the pharmacokinetic parameters for ddG are listed in Table 2 . The disposition of ddG was similar to that of ddI (Table 2 ; Fig. 3A) , with a total clearance of 0.70 liters/kg/h and a terminal half-life of 1.7 h. However, the penetration of ddG into CSF (8.5%) exceeded that of ddI (4.8%; P ϭ 0.05).
Like ddA, the 6-halo-ddG analogs were very rapidly eliminated, and the rate of 6-halo-ddG elimination was consistent with the observed in vitro rates of metabolism of these analogs (i.e., Cl-ddG Ͼ I-ddG). Cl-ddG was not detectable in plasma or CSF, regardless of whether DCF was present in the collection tubes. I-ddG was measurable in both plasma and CSF (Table 3 ; Fig. 3C) , with a mean total clearance of 23 liters/h/kg and a half-life of 0.44 h. Unlike ddA, all of which is apparently converted to ddI, the conversion of the 6-halo-ddG analogs to ddG appears to be incomplete. The mean AUCs of ddG following administration of equimolar doses of ddG, Cl-ddG, or I-ddG were 194, 92.3, and 55.5 M ⅐ h, respectively, and the bioavailabilities of ddG from Cl-ddG and I-ddG were 48 and 29%, respectively. The pharmacokinetic model of the disposition of I-ddG (Fig. 1 ) incorporated a rate constant for metabolism of I-ddG to ddG (k dm ) and a rate constant for elimination by other pathways (k el ), and in two of three animals k el exceeded k dm (Table 3) .
The penetration of ddG into CSF (CSF-to-plasma AUC ratio) following administration of the 6-halo-ddG analogs was significantly greater than the degree of penetration of ddG into CSF achieved with the administration of ddG. The CSF-toplasma ratio (Table 2 ) of ddG following ddG administration was 8.5%, compared with 24% (P ϭ 0.030) for Cl-ddG as a prodrug and 17% (P ϭ 0.034) for I-ddG as a prodrug. Cl-ddG was not detected in the plasma or CSF, and the penetration of I-ddG into CSF was 9.4%, so the pharmacokinetic data in our primate model does not appear to support the hypothesis that the enhanced penetration of ddG into CSF following 6-haloddG administration is the result of penetration of the 6-haloddG analogs and subsequent conversion to ddG. There was no significant difference in exposure of CSF to ddG (AUC) for ddG (12.1 M ⅐ h) compared with those for Cl-ddG (18.8 M ⅐ h; P ϭ 0.14) and I-ddG (9.3 M ⅐ h; P ϭ 0.48).
FIG. 1.
Pharmacokinetic models used to describe plasma and CSF concentration-time data for ddI, ddI after administration of ddA, ddG, and ddG after administration of Cl-ddG (A) and I-ddG and ddG after administration of I-ddG (B). In both models it is assumed that the transfer of drug to and from the CSF compartment has no significant impact on the concentration of drug in the other body compartments because of the relatively small volume of the CSF compartment and the low concentration of drug in this compartment. Therefore, there is no term in the equations for C or C c that describes the transfer of drug to and from the CSF. (A) C c and C p are the drug concentrations in the central and peripheral compartments at time t; k 0 is the rate of drug infusion; k cel is the elimination rate constant; k cp , k pc , k ccf , and k cfc are the rate constants describing drug transfer between compartments; and V C and V CF are the volumes of the central and CSF compartments. (B) C is the concentration of I-ddG in a single body compartment at time t; C c and C p are the concentrations of ddG in the central and peripheral compartments, respectively; C ICF and C CF are the concentrations of I-ddG and ddG in the CSF, respectively; k 0 is the rate of I-ddG infusion; k dm is the rate of metabolism of I-ddG to ddG, and k el is the rate of elimination by all other routes; k cel is the elimination rate constant for ddG; k iccf and k icfc are the rate constants describing the transfer of I-ddG to and from CSF, respectively; k cp , k pc , k ccf , and k cfc are the rate constants describing the transfer of ddG between compartments; V is the volume of the body compartment in which I-ddG is distributed; V C is the volume of the central compartment for ddG; and V CF is the volume of the CSF compartment.
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DISCUSSION
The metabolism of ddA and the 6-halo-ddG analogs in the non-human primate model was extremely rapid. ADA, the enzyme responsible for deaminating ddA to ddI and dehalogenating the 6-halo-ddG compounds to ddG (17) , is plentiful and ubiquitous. In humans the highest levels of enzyme were found in the spleen, intestine, lung, and colon, but substantial levels were also present in the brain, liver, and erythrocytes (10) . The nearly instantaneous and complete deamination of ddA observed in the present study is consistent with the results reported for humans (9) .
In contrast, the dehalogenation of the 6-halo-ddG analogs to ddG was incomplete and the bioavailability of ddG from ClddG (48%) and I-ddG (29%) was proportional to the rate of ADA-catalyzed hydrolysis in vitro (17) . In these studies, the rate of ddA deamination was approximately 20-fold more rapid than the rate of Cl-ddG dehalogenation, which was in turn approximately 4-fold more rapid than the rate of I-ddG dehalogenation (17) . In addition to dehalogenation by ADA, the 6-halo-ddG compounds are apparently catabolized rapidly via other metabolic pathways to account for the incomplete conversion to ddG and the inability to detect Cl-ddG in the plasma of non-human primates. In mice the 6-halo-ddG compounds also undergo conjugation with glutathione (23) .
The penetration of ddI (4.8%) into the CSF of non-human primates is limited compared with that of zidovudine (20%), which was studied in the same animal model (5) . This model proved to be predictive of the degree of zidovudine penetration in humans under steady-state conditions. Children receiving zidovudine by continuous intravenous infusion had a steady-state CSF-to-plasma ratio of 24% (2) . Single lumbar CSF samples have been obtained from patients treated during initial clinical trials of ddI. In children, ddI was not detectable (less than 0.1 M) in 17 of 20 CSF samples obtained 2 h after administration of an oral dose (1) . In adults, a single CSF sample was obtained 1 h after the end of a 1.5-h intravenous infusion, and the ratio of the ddI concentration in CSF to that in plasma ranged from 12 to 27% (9). It is worth noting that when the CSF-to-plasma ratio was calculated from simultaneous, single concentrations in CSF and plasma under non-steady-state conditions in our model, we observed an 88-fold range of values. Even within a single animal the CSF-to-plasma concentration ratio calculated by this method varied by as much as 58-fold. As can be gleaned from Fig. 2 , this wide range is the result of differences in the shape of the drug profiles in plasma and CSF. The use of the AUCs in CSF and plasma to estimate penetration into CSF, as was used in the present study, provides a ratio of overall drug exposure in each compartment and is independent of the shape of the concentration-time curves.
We also observed in the model that the ratio of simultaneous concentrations in CSF and plasma from samples taken Ն2 h after the start of drug administration, as was done in the adults receiving ddI, always overestimated the penetration into CSF calculated from the ratio of the AUCs. In the initial adult trial of zidovudine, simultaneous, single CSF and plasma samples were obtained from six patients at various times (1.8 to 4 h) after administration of a dose. The CSF-to-plasma concentration ratios ranged from 15 to 135% and were highly correlated with sample timing, with later samples showing higher CSF-toplasma ratios (11) . These estimates of the penetration of zidovudine into CSF exceeded the more accurate estimates obtained in children studied under steady-state conditions. Use of single, simultaneous drug concentrations in CSF and plasma after administration of a bolus or oral dose of a drug to calculate penetration into CSF does not accurately reflect the overall exposure of CSF to drug, particularly when concentrations over a range of time points are obtained from different subjects. Comparing concentrations in CSF and plasma at steady state (during a continuous intravenous infusion) or measuring concentrations at multiple time points within the same subject and comparing the AUCs in CSF to those in plasma are more valid measures of overall exposure of CSF to drug.
The penetration of ddG into CSF (8.5%) exceeded that of ddI (4.8%), but it is difficult to predict whether this 1.8-fold difference will be clinically significant. The penetration of ddG into CSF was enhanced by the administration of the 6-haloddG prodrugs, although the mechanism of this enhanced penetration is unclear. A similar result was reported for the 6-haloddI analogs studied in a rat model (16) . In this rodent model the concentration of the 6-halo-ddI analogs in plasma exceeded the concentration of ddI, and the levels of penetration of Cl-ddI and I-ddI into the CSF were 64 and 42%, respectively, and those into the brain parenchyma were 67 and 48%, respectively. Conversion of the lipophilic 6-halo-ddI prodrugs to ddI by ADA in the CNS was felt to account for the enhanced penetration of ddI into CSF and brain parenchyma in that model. In non-human primates, Cl-ddG was not detectable in plasma or CSF and the penetration of I-ddG into CSF was limited (9.4%), so it is difficult to invoke this same mechanism to account for the enhanced penetration of ddG into CSF with our model. It is possible that unmeasured metabolites of the 6-halo-ddG prodrugs could serve as the transport forms that enter the brain and CSF and that these metabolites are subsequently converted to ddG, similar to the role played by the 6-halo-ddI compounds in rats. Another possible explanation for the apparent enhanced penetration of ddG into CSF following administration of Cl-ddG and I-ddG is the presence of a capacity-limited or saturable influx mechanism for the entry of ddG into the CNS. With the higher concentrations achieved in plasma with the administration of ddG compared with those achieved with the administration of Cl-ddG and I-ddG, transport into the CNS could be saturated and the concentration of drug in the CSF relative to that in plasma would be lower. Such a phenomenon has been observed with another nucleoside analog, cytarabine, for which the CSF-to-plasma concentration ratio declined from 42 to 18% as the dose was increased from 2 to 18 g/m 2 (6). The potential clinical advantage for the 6-halo-ddG prodrugs will ultimately be dependent on whether toxicity is related to systemic exposure (AUC) to ddG, in which case larger doses of the 6-halo-ddG prodrugs will be tolerated relative to a dose of ddG and higher absolute concentrations of ddG may be achieved in the CSF and brain.
